文档介绍：非霍奇金淋巴瘤BCL
作者:刘元华, Christophe Leboeuf, 金晓龙,肖家诚, Anne Janin, 陈赛娟,赵维莅
【摘要】本研究探讨78例非霍奇金淋巴瘤BCL-XL表达和突变的发生率及其临床意义。应用激光微切割技术从淋巴结组织中特异地分离淋巴瘤细胞,用实时定量RT-PCR法检测淋巴瘤组织和淋巴瘤细胞中BCL-XL的表达,PCR直接测序法检测BCL-XL的突变情况。结果表明:与淋巴结反应性增生(15例)相比,滤泡性淋巴瘤(30例)组织和微切割的淋巴瘤细胞均高表达BCL-XL(<),而T细胞淋巴瘤(24例)和弥漫性大B细胞淋巴瘤(24例)中BCL-XL表达无明显升高。在滤泡性淋巴瘤中,BCL-XL高表达的患者常伴多个淋巴结外器官累及(P=),血清乳酸脱氢酶水平升高(P=),国际预后指数分组多为高危组(P=),患者总生存期短(P=)。突变检测发现1例滤泡性淋巴瘤BCL-XL的同义突变(密码子 109 ACA→ACC)。结论:BCL-XL表达与滤泡性淋巴瘤的疾病进展和患者预后密切相关。
【关键词】非霍奇金淋巴瘤;BCL-XL基因;基因表达;基因突变
BCL-XL Expression and Mutation in Non-Hodgkin′s Lymphoma
Abstract The study ed to investigate the BCL-XL expression and mutation, and its clinical significance in non-Hodgkin′s lymphoma. Lymphoma cells icrodissection. BCL-XL expression from lymphoma tissue and microdissected lymphoma cells easured by using real-time quantitative reverse transcription-polymerase chain reaction. BCL-XL mutation phoma (n=30), both in lymphoma tissue (P=) and in microdissected lymphoma cells (P<). No significant rise of BCL-XL expression phoma (n=24) and diffuse large B cell lymphoma (n=24). In follicular lymphoma, high BCL-XL level ultiple extranodal involvement (P=), elevated lactate dehydrogenase level (P=), high-risk international prognostic index (P=) and a short overall survival time (P=). Mutation analysis revealed one syn